Business Context and Reporting Period
Company: Innovative Acquisitions Corp. (Note: Input metadata referenced "PUMA BIOTECHNOLOGY, INC." but the filing text identifies the registrant as Innovative Acquisitions Corp.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2008
Business Status: The Company is a "blank check" shell company incorporated in Delaware on April 27, 2007. It has no specific business plan other than to seek a business combination (merger or acquisition) with an unidentified target. It has no active operations, no employees other than management, and no revenue.
Key Financial Metrics
| Metric | 2008 | 2007 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(14,083) | $(15,093) |
| Cash and Cash Equivalents | $73 | $1,407 |
| Total Assets | $73 | $1,407 |
| Total Liabilities | $2,249 | $0 |
| Stockholders' Equity (Deficit) | $(2,176) | $(1,407) |
| Outstanding Common Shares | 3,000,000 | 3,000,000 |
Liquidity: The Company had only $73 in cash as of December 31, 2008, against $2,249 in accounts payable. Management states there is substantial doubt about the Company's ability to continue as a going concern without additional financing.
Material Changes vs. Prior Period
- Cash Position: Cash decreased by $1,334 (from $1,407 to $73) due to operating costs exceeding capital contributions.
- Liabilities: Accounts payable increased from $0 in 2007 to $2,249 in 2008, representing unpaid professional fees.
- Capital Contributions: The Company received $10,500 in capital contributions from existing stockholders during 2008 to fund operations, compared to $4,500 in 2007.
- Accumulated Deficit: The accumulated deficit grew from $(15,093) to $(29,176) over the cumulative period from inception.
Outlook, Risks, and Management Commentary
Outlook: The Company's sole objective is to locate and acquire a target business. It anticipates incurring costs for filing reports and investigating acquisition targets. It expects to fund these costs through treasury funds, deferral of fees, or additional loans/investments from stockholders and management.
Risks and Contingencies:
- Going Concern: The auditors have issued a "going concern" opinion, noting that recurring losses and the lack of revenue raise substantial doubt about the Company's ability to continue operations.
- Financing Dependency: The Company is entirely dependent on related parties for funding. If funding is unavailable, the Company may not be able to implement its plan.
- Acquisition Risk: There is no assurance a business combination will occur. Any target acquired may be financially unstable or in early development stages.
- Dilution: Future acquisitions may result in substantial dilution to existing shareholders if the transaction is structured as a tax-free reorganization.
Investor Verification Checklist
- Identity Discrepancy: Verify why the request metadata listed "PUMA BIOTECHNOLOGY, INC." while the filing is for "Innovative Acquisitions Corp."
- Capital Sufficiency: Confirm if the $73 cash balance is sufficient to meet the $2,249 in accounts payable and ongoing filing costs.
- Related Party Support: Assess the commitment of the three directors (Robert Johnson, Faraaz Siddiqi, Kapil Munjal) to provide further capital contributions, as the company relies on them for survival.
- Shell Status: Confirm the Company remains a shell company with no assets other than cash and no operations, as defined by SEC Rule 12b-2.
- Going Concern: Review the auditor's report (Malone & Bailey, PC) regarding the substantial doubt on the Company's ability to continue as a going concern.